Get the Stockscreener App
1.1217
0.88%
-0.0183
Therapeuticsmd Inc stock is traded at $1.1217, with a volume of 47,568.
It is down -0.88% in the last 24 hours and up +23.88% over the past month.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
See More
Previous Close:
$1.14
Open:
$1.11
24h Volume:
47,568
Relative Volume:
0.17
Market Cap:
$11.65M
Revenue:
$996.00K
Net Income/Loss:
$-6.09M
P/E Ratio:
-2.1164
EPS:
-0.53
Net Cash Flow:
$-9.76M
1W Performance:
+11.88%
1M Performance:
+23.88%
6M Performance:
-28.93%
1Y Performance:
-39.57%
1-Day Range:
$1.08
$1.1799
1-Week Range:
$0.97
$1.1799
52-Week Range:
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
Name
Therapeuticsmd Inc
Sector
Phone
561-961-1900
Address
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.13 | 11.65M | 996.00K | -6.09M | -9.76M | -0.53 |
|
ZTS
Zoetis Inc
|
152.91 | 66.32B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.99 | 46.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 46.11B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.78 | 16.87B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.94 | 12.79B | 2.76B | 1.11B | 898.10M | 22.77 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
Therapeuticsmd Inc Stock (TXMD) Latest News
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com - Defense World
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock By Investing.com - Investing.com Canada
TherapeuticsMD director Tommy Thompson acquires $325 in stock - Investing.com Australia
TherapeuticsMD director Tommy Thompson acquires $325 in stock By Investing.com - Investing.com Canada
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock - Investing.com
TherapeuticsMD CEO Marlan Walker buys $489 in common stock By Investing.com - Investing.com South Africa
TherapeuticsMD CEO Marlan Walker buys $489 in common stock - Investing.com
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
Mayne Pharma Faces Legal Challenge from TherapeuticsMD - TipRanks
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock - Investing.com Australia
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock By Investing.com - Investing.com India
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsmdFiles Lawsuit Against Mayne Pharma For Breach Of Contract - marketscreener.com
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023) - Yahoo Finance
TherapeuticsMD Reports Improved Financial Performance - TipRanks
DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 -- TXMD - ACCESS Newswire
TherapeuticsMD Inc. (TXMD) reports earnings - Quartz
TherapeuticsMD Reports Reduced Losses and Revenue Growth - TipRanks
TherapeuticsMD Announces Full Year 2024 Financial Results - Business Wire
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Therapeuticsmd Inc Stock (TXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Therapeuticsmd Inc Stock (TXMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Walker Marlan D | Chief Executive Officer |
Apr 14 '25 |
Buy |
1.00 |
490 |
489 |
73,639 |
| Walker Marlan D | Chief Executive Officer |
Apr 10 '25 |
Buy |
0.86 |
1,167 |
1,000 |
73,149 |
| Walker Marlan D | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.87 |
1,136 |
994 |
71,982 |
| Collins Cooper C. | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
60,516 |
| Naughton Gail K | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
8,500 |
| Thompson Tommy G | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
14,454 |
| Walker Marlan D | Chief Executive Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
8,281 |
0 |
70,846 |
| Collins Cooper C. | Director |
Aug 22 '24 |
Buy |
1.73 |
4,094 |
7,099 |
52,016 |
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):